Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

PK Study in Subjects With Severe Hepatic Impairment (MCI-186-E05 HP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03664544
Recruitment Status : Completed
First Posted : September 10, 2018
Last Update Posted : April 16, 2019
Sponsor:
Information provided by (Responsible Party):
Mitsubishi Tanabe Pharma Corporation

Brief Summary:
This is an open-label, single-dose study in male and female subjects with severe hepatic impairment and in male and female subjects with normal hepatic function.

Condition or disease Intervention/treatment Phase
Severe Hepatic Impairment Healthy Drug: MCI-186 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MCI-186 in Subjects With Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function
Actual Study Start Date : November 6, 2018
Actual Primary Completion Date : March 25, 2019
Actual Study Completion Date : March 25, 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Edaravone

Arm Intervention/treatment
Experimental: Subjects with severe hepatic impairment
HP PK MCI-186
Drug: MCI-186
30 mg MCI-186 will be administered intravenously over 60 minutes.
Other Names:
  • Edaravone
  • Radicava
  • Radicut

Experimental: Subjects with normal hepatic function
NHV PK MCI-186
Drug: MCI-186
30 mg MCI-186 will be administered intravenously over 60 minutes.
Other Names:
  • Edaravone
  • Radicava
  • Radicut




Primary Outcome Measures :
  1. Pharmacokinetic parameters of MCI-186: Peak drug concentration (Cmax) [ Time Frame: Day 1 to 3 ]
  2. Pharmacokinetic parameters of MCI-186: Area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-last) [ Time Frame: Day 1 to 3 ]
  3. Pharmacokinetic parameters of MCI-186: Area under the concentration-time curve from time zero to infinity (AUC0-∞) [ Time Frame: Day 1 to 3 ]

Secondary Outcome Measures :
  1. Incidence of adverse events (AEs) and serious adverse events [ Time Frame: Day -1 to Day 7 ]
  2. Pharmacokinetic parameters of MCI-186: Half-life (t½) [ Time Frame: Day 1 to 3 ]
  3. Pharmacokinetic parameters of MCI-186: Time to reach peak concentration (tmax) [ Time Frame: Day 1 to 3 ]
  4. Pharmacokinetic parameters of MCI-186: Terminal elimination rate constant (λZ) [ Time Frame: Day 1 to 3 ]
  5. Pharmacokinetic parameters of MCI-186: Total clearance (CL) [ Time Frame: Day 1 to 3 ]
  6. Pharmacokinetic parameters of MCI-186: Volume of distribution at steady state (Vss) [ Time Frame: Day 1 to 3 ]
  7. Pharmacokinetic parameters of MCI-186: Volume of distribution during the terminal phase (VZ) [ Time Frame: Day 1 to 3 ]
  8. Pharmacokinetic parameters of MCI-186: Mean residence time (MRT) [ Time Frame: Day 1 to 3 ]
  9. Pharmacokinetic parameters of MCI-186: Unbound area under the concentration-time curve from time zero to infinity (AUCu0-∞) [ Time Frame: Day 1 to 3 ]
  10. Pharmacokinetic parameters of MCI-186: Unbound total clearance (Clu) [ Time Frame: Day 1 to 3 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

All subjects

  • 1. Able to provide written informed consent to participate in this study after reading the participant information sheet and Informed Consent Form (ICF), and after having the opportunity to discuss the study with the Investigator or designee.
  • 2. Male or female subjects age 18 to 75 years (inclusive) at signature of the ICF.
  • 3. In the Investigator's opinion, subject is able to understand the nature of the study and any risks involved in participation, and willing to cooperate and comply with the Protocol restrictions and requirements.
  • 4. A body weight of ≥50 kg and a body mass index (Quetelet index) ranging from 18 to 37 kg/m2 (inclusive) at Screening and Day -1.
  • 5. Female subjects who are:

    1. postmenopausal for at least 1 year, confirmed by follicle-stimulating hormone assessment (>40 mIU/mL), or
    2. surgically sterilised (hysterectomy, bilateral oophorectomy or salpingectomy), or
    3. congenital sterility. Female subjects of child-bearing potential must practice effective contraception (see Protocol body) from the Screening Visit or at least 2 weeks before IMP administration, until 30 days after IMP dosing. Male subject must practice effective contraception from the time of IMP dosing until 90 days after IMP dosing. Adhering to strict abstinence is considered an accepted contraceptive method.

Hepatic impaired subjects (in addition)

  • 6. Diagnosis of cirrhosis due to parenchymal liver disease, which is documented in the medical history and physical examination and confirmed by at least one of the following: hepatic ultrasound, computed axial tomography scan, magnetic resonance imaging and/or liver biopsy. A Child-Pugh classification score of 10 to 14 obtained during the Screening period (i.e., within 21 days of IMP administration).
  • 7. Chronic (>6 months) and stable hepatic impairment defined as no clinically significant change in disease status at least 14 days before Screening.
  • 8. Acceptable clinical conditions in the opinion of the Investigator on the basis of a physical examination, medical history, 12-lead electrocardiogram (ECG), vital signs and clinical laboratory tests (biochemistry, haematology, coagulation and urinalysis) at Screening, Day -1 and pre-dose on Day 1. Subjects with stable mild chronic concurrent diseases, such as degenerative joint disease, controlled diabetes, hypertension or hyperlipidaemia, etc. may be included.

Healthy subjects (in addition)

  • 9. Subjects with normal hepatic function confirmed with tests within the normal reference range or results with minor deviations which are not considered by the Investigator to be clinically significant.
  • 10. Good health and free from clinically significant illness or disease in the opinion of the Investigator on the basis of a physical examination, medical history, ECG, vital signs and clinical laboratory tests (biochemistry, haematology, coagulation and urinalysis) at Screening, Day -1 and pre-dose on Day 1.

Exclusion Criteria:

All subjects

  • 1. Presence or history of severe allergy to food, or any medical product or relevant excipient that is of clinical significance.
  • 2. Subjects who have previously been administered MCI-186.
  • 3. As a result of the medical screening process, the Investigator considers the subject not suitable for the study.
  • 4. Clinically significant 12-lead ECG abnormalities, including but not limited to, corrected QT interval using Fridericia's formula (QTcF) of >450 ms (male subjects) or >470 ms (female subjects) at Screening, Day -1 or before dosing.
  • 5. Any other history or condition (surgical or medical) of disease which will increase the risk to the subject, will affect the PK of the study drug, or will otherwise influence the assessments to be made in this study, in the opinion of the Investigator. Subjects who have undergone cholecystectomy may be included.
  • 6. History of drug abuse or tested positive for alcohol or drugs of abuse at Screening and Day -1, excluding drugs which may cause a positive drug or abuse test if medically indicated or prescribed.
  • 7. Subjects who regularly, or on average, drink more than 35 units of alcohol per week (one unit is equivalent to 300 mL of beer, 25 mL of spirits or 150 mL of wine).
  • 8. Presence of active infection requiring antibiotics.
  • 9. Positive test for human immunodeficiency virus antigen/antibody at Screening.
  • 10. Donation of one or more units of blood (450 mL) within 3 months prior to Screening, or plasma in the 7 days prior to Screening, or platelets in the 6 weeks prior to Screening, or the intention to donate blood within 3 months after the last Follow-up assessment.
  • 11. Participation in another study within the last month (if single dose), or at least 4 months (if multiple dose), or within 10 times the half-life of the respective drug (whichever is longer) before Screening. For biologics, the minimum period is at least 6 months before Screening, the period of the pharmacodynamic effect, or 10 times the half life of the respective drug, whichever is longer.
  • 12. Subject is currently taking non-permitted concomitant medication. The subjects with normal hepatic function are restricted from use of any concomitant medications (including paracetamol) unless discussed and agreed with the Sponsor. In subjects with hepatic impairment, the use of prescribed medications is permitted for hepatic or concomitant disease as described in the Protocol body.
  • 13. Not willing to abstain from consumption of coffee, tea, cola, energy drinks or chocolates from admission to the unit (Day -1) to discharge from the unit (Day 3).
  • 14. Uncontrolled, or untreated hypertension defined as a mean of three repeated measurements of systolic blood pressure >180 mmHg and/or diastolic blood pressure >100 mmHg.
  • 15. Subjects have estimated glomerular filtration rate <60 mL/min/1.73 m2 as determined by Modification of Diet in Renal Disease formula.
  • 16. Any condition associated with dehydration.
  • 17. Female subjects:

    1. who have a positive pregnancy test at Screening or on Day -1.
    2. who are pregnant, lactating or planning to become pregnant during the study.

Hepatic impaired subjects (in addition)

  • 18. Subjects with severe ascites or pleural effusion which will, in the opinion of the Investigator, adversely affect the subject's ability to participate in the study.
  • 19. Subjects with severe encephalopathy (Grade III or IV).
  • 20. Subjects with sclerosing cholangitis.
  • 21. Serum albumin <2.0 g/dL.
  • 22. Haemoglobin <10 g/dL.
  • 23. Start of any new medication or any changes to a current dosage within 14 days before IMP administration.

Healthy subjects (in addition)

  • 24. History or presence of any parenchymal hepatic disease.
  • 25. Positive test for hepatitis B surface antigen or hepatitis C virus antibody.
  • 26. History of or active suicidal ideation, or suicide attempt as evidenced by positive response to either Question 4 (active suicidal ideation with some intent to act) or Question 5 (active suicidal ideation with specific plan and intent) on the Columbia-Suicide Severity Rating Scale (C-SSRS; Screening Version).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03664544


Locations
Layout table for location information
Czechia
Investigational Centre
Prague, Czechia
Hungary
Investigational Centre
Miskolc, Hungary
Slovakia
Investigational Centre
Bratislava, Slovakia
Sponsors and Collaborators
Mitsubishi Tanabe Pharma Corporation
Investigators
Layout table for investigator information
Study Director: General Manager Mitsubishi Tanabe Pharma Europe Ltd

Layout table for additonal information
Responsible Party: Mitsubishi Tanabe Pharma Corporation
ClinicalTrials.gov Identifier: NCT03664544     History of Changes
Other Study ID Numbers: MCI-186-E05
2018-001163-23 ( EudraCT Number )
First Posted: September 10, 2018    Key Record Dates
Last Update Posted: April 16, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Mitsubishi Tanabe Pharma Corporation:
Severe Hepatic Impairment
Healthy

Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Diseases
Digestive System Diseases
Edaravone
Free Radical Scavengers
Antioxidants
Molecular Mechanisms of Pharmacological Action
Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs